DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
03/02/2023 - 05:30 PM
Montrouge, France, March 2, 2023
DBV Techn ologies a nnounces f iling of 202 2 Annual Report on Form 10-K and 202 2 Universal Registration Document
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) and the filing of its 2022 Universal Registration Document (“URD”) for the year ended December 31, 2022 with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
These documents can be accessed on the Investors section of the Company's website at www.dbv-technologies.com . In addition, the URD is available on the AMF’s website at www.amf-france.org and the Form 10-K is available on the SEC’s website at www.sec.gov .
Printed copies of both documents are available, free of charge, at the Company’s headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.
About DBV Technologies
Investor Contact anne.pollak@dbv-technologies.com
Media Contact angela.marcucci@dbv-technologies.com
DBVT Rankings
#3835 Ranked by Stock Gains
DBVT Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
France
City
Montrouge
About DBVT
dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and
